Results of a randomized, double ‐blind, active‐controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder
ConclusionsPropiverine ER 30 mg was confirmed to be an effective and well‐tolerated treatment option for patients with OAB symptoms. This first head‐to‐head study showed non‐inferiority of propiverine ER 30 mg compared with tolterodine ER 4 mg.
CONCLUSION: LACS allowed the anatomical reconstruction of the pelvic floor and proved to be a minimally invasive, fast, effective, safe and reproducible technique. More series are needed to evaluate its role against laparoscopic colposacropexy.
PMID: 33032847 [PubMed - as supplied by publisher]
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Authors: Baldissera Aradas JV, Polo Hernández R, Merenciano F, Amat M, Climent P, Ferrero Doria RTags: Actas Urol Esp Source Type: research
Three-dimensional ultrasound urodynamics can be used to identify differences in bladder shape comparing individuals with and without OAB. This method may be used to identify a subset of OAB patients with abnormal bladder shapes which may play a role in the pathophysiology of their OAB symptoms.